Pharmaceuticals Industry Trends United Kingdom - 2022

Market Monitor

  • Verenigd Koninkrijk
  • Chemie/Farmacie

15 mrt 2022

Large backlog of medical treatments to sustain growth in the coming years

IT UK pharma credit risk 2022

Pharmaceuticals value added output in the UK levelled off in 2021 after a strong 13.6% increase in 2020, which still leaves it 13% above the 2019 pre-pandemic level. The vaccination rollout and demand for pandemic-related drugs (e.g. medications to treat fever, drugs for intensive care) has driven growth, resulting in high profit margin increases for producers, and to a lesser extent for wholesalers and pharmacies. However, for some businesses border checks and regulatory burdens, due to Brexit, have raised costs and has delayed delivery of goods. Some businesses moved their operations to other European countries in order to retain easier market access in the EU.

IT UK pharma output 2022

There is still a large backlog of non-Covid related medical and elective care hospital treatments. The government and the NHS recently announced they would address this with a major catch-up programme over the next three years. This should sustain ongoing demand for pharmaceuticals.

Another growth driver in the mid- and long-term will be ageing of population. This will in particular spur demand for speciality drugs related to chronic diseases. However, despite higher public healthcare spending in the short-term, cost constraints will remain an issue in the long-term, and there will be pressure by the government and public health authorities on pharmaceutical businesses to lower sales costs of drugs. Rising imports of cheaper generics could be an outcome of cost pressures in the health system.

Payments in the industry take about 60 days on average, but longer payment terms imposed by the NHS are common. Payment behaviour has been very good over the past two years, and the number of both payment delays and insolvencies has been extraordinarily low in 2021.

With the expiry of large pandemic-related government support measures both payment delays and insolvencies could increase slightly year-on-year in 2022. However, this would only mean a reversion to the already low and stable levels seen in the years prior to the pandemic. Due to low credit risk, the robust demand situation and the financial strength of most businesses, our underwriting stance remains open across all segments.







Elke publicatie die beschikbaar is op of vanaf onze websites, zoals, maar niet beperkt tot webpagina's, rapporten, artikelen, publicaties, tips en nuttige content, blogs, infographics, video's (hierna ‘Publicatie’) wordt louter ter informatie verstrekt en is niet bedoeld als beleggingsadvies, juridisch advies of enige aanbeveling aan de lezer(s) met betrekking tot specifieke transacties, investeringen of strategieën. Lezers zijn zelf verantwoordelijk voor het nemen van commerciële en andere beslissingen omtrent de verstrekte informatie. Hoewel Atradius al het noodzakelijke heeft gedaan om te verzekeren dat de informatie in enige Publicatie verkregen is van betrouwbare bronnen, kan Atradius niet verantwoordelijk gesteld worden voor fouten of omissies, of voor de resultaten verkregen door gebruik van deze informatie. Alle informatie in enige Publicatie wordt gegeven ‘zoals ze is’, zonder garantie op volledigheid, accuraatheid, tijdsgebondenheid, of op de resultaten verkregen door gebruik van de publicatie, en zonder garantie van enige soort, uitdrukkelijk of geïmpliceerd. In geen geval zal Atradius, haar gerelateerde partners of corporaties, of de partners, agenten of werknemers hiervan verantwoordelijk gesteld kunnen worden voor enige genomen beslissing of actie die zij zouden nemen op basis van de in enige Publicatie verstrekte informatie, of voor enig verlies van kansen, winstderving, productieverlies, omzetverlies of gevolgschade, speciale of soortgelijke schade van welke aard dan ook, zelfs wanneer de lezer in kennis is gesteld van de mogelijkheid van dergelijke verliezen of schade.